Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
CARLSBAD, Calif., Nov. 30, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that the biopharmaceutical company AstraZeneca has initiated a Phase 2b clinical trial of ION
Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development
05:15pm, Monday, 23'rd Nov 2020
CARLSBAD, Calif., Nov. 23, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the biopharmaceutical company AstraZeneca has licensed ION455, an investigational antise
CARLSBAD, Calif., Nov. 13, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that new data for ION449, an investigational antisense medicine designed to reduce plasma lev
Ionis' antisense technology to be featured during virtual RNA at the Bench and Bedside II Conference
07:05am, Tuesday, 10'th Nov 2020
CARLSBAD, Calif., Nov. 10, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that accomplished Ionis scientists will highlight the company's pioneering advancements in re
Ionis to present at upcoming virtual investor conferences
07:05am, Monday, 09'th Nov 2020
CARLSBAD, Calif., Nov. 9, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the
LONDON--(BUSINESS WIRE)--Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today that the Scottish Medicines Consortium (SMC) has enabled access to
Ionis and Akcea Recognize FCS Awareness Day With Global Community Efforts to Celebrate Unsung Heroes
03:00am, Friday, 06'th Nov 2020
BOSTON & CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals (NASDAQ: IONS) and its wholly owned subsidiary, Akcea Therapeutics, today recognize the 3rd annual Familial Chylomicronemia Syndrome (
Ionis Pharmaceuticals' (IONS) CEO Brett Monia on Q3 2020 Results - Earnings Call Transcript
07:19pm, Wednesday, 04'th Nov 2020
Ionis Pharmaceuticals' (IONS) CEO Brett Monia on Q3 2020 Results - Earnings Call Transcript
What's Behind Ionis Pharmaceuticals' Q3 Earnings Disappointment
12:00pm, Wednesday, 04'th Nov 2020
The main problem: a lackluster performance for Spinraza.
Recap: Ionis Pharmaceuticals Q3 Earnings
07:24am, Wednesday, 04'th Nov 2020
Shares of Ionis Pharmaceuticals (NASDAQ:IONS) moved higher by 1.6% in pre-market trading after the company reported Q3 results.
Ionis reports third quarter 2020 financial results and recent business achievements
07:00am, Wednesday, 04'th Nov 2020
CARLSBAD, Calif., Nov. 4, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the third quarter of 2020 and recent business highlights. "We took an
Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen (AKCEA-ANGPTL3-LRx)
06:00pm, Tuesday, 03'rd Nov 2020
CARLSBAD, Calif. and BOSTON, Nov. 3, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its wholly owned subsidiary Akcea Therapeutics, Inc., today announced that Pfizer Inc. (NYSE: P
Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product
07:00am, Friday, 30'th Oct 2020
BOSTON and CARLSBAD, Calif., Oct. 30, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its wholly owned subsidiary, Akcea Therapeutics, received the Prix Galien USA Award for the Be
Ionis With Akcea: Still A Bargain (NASDAQ:IONS)
06:08am, Wednesday, 21'st Oct 2020
Akcea merged back into Ionis. Ionis has commercial revenues and an immense clinical pipeline.
William Blair Analysts Decrease Earnings Estimates for Ionis Pharmaceuticals Inc (NASDAQ:IONS)
01:32am, Saturday, 17'th Oct 2020
Ionis Pharmaceuticals Inc (NASDAQ:IONS) – Analysts at William Blair dropped their Q3 2020 earnings per share (EPS) estimates for shares of Ionis Pharmaceuticals in a research note issued to investor
